Autoimmune hemolytic anemia (AIHA) is a well-recognized complication following allogeneic hematopoietic SCT (HSCT). Compared with the incidence of one to two cases per 100 000 in the normal adult population, 1 AIHA is estimated to occur in 3-5% of adult HSCT patients. 2, 3 In the largest study of pediatric patients to date, published in 2004, the incidence of all types of AIHA was 6% at 1 year after transplant. 4 The cause for this increased incidence post transplant is poorly understood, but is likely because of an incomplete reconstitution of the immune system and immune dysregulation. As has been observed in the adult HSCT patient population, 2,3 the majority of the pediatric patients are refractory to standard therapy for AIHA. As a result, the mortality rate is high (53%) because of hemolysis and infectious complications that develop as a consequence of the immunosuppressive treatments for AIHA. 4 Autoimmune hemolytic anemia following HSCT is usually mediated by warm reactive, IgG autoantibodies. Cold reactive, IgM autoantibodies that have reactivity at 30 1C or higher can also cause clinically significant hemolysis, but this has been rarely described in the HSCT setting, with only two pediatric cases reported in the literature to our knowledge. 5, 6 Little is known about the clinical course and optimal management of cold AIHA in the HSCT population, but in general, cold AIHA is not responsive to standard therapies such as steroids or splenectomy. In this report, we describe the successful treatment of a pediatric patient with severe cold AIHA following allogeneic HSCT, using rituximab.
The patient is a 9-year-old boy with CML, who received a 9/10 HLA-matched sibling donor HSCT during his chronic phase. His pre-transplant conditioning consisted of a myeloablative regimen with BU and CY. Early signs of engraftment were seen during the second week after transplant and he was discharged home at day þ 19. His post transplant course was significant only for grade II GVHD of the skin, which resolved.
He was admitted at 5 months after transplant for having a fever of 101 1F. His immune suppression at this time consisted of tapering doses of oral CYA and prednisone. He was also receiving monthly i.v.Ig. Multiple blood cultures drawn upon admission grew coagulase-negative staphylococcal species and he was treated with a 14-day course of antibiotics, to which he responded well.
Laboratory evaluation also showed severe anemia, with an Hb concentration of 5.7 g/100 ml, compared with 10.0 g/100 ml 1 month earlier. Despite a transfusion of three units of packed RBCs, his Hb remained low at 4.9 g/100 ml. Further laboratory analysis revealed an elevated total bilirubin (5 mg/100 ml) and lactate dehydrogenase, as well as an undetectable haptoglobin level. His urine was noted to be dark, consistent with significant intravascular hemolysis. Direct Coombs test was positive for both IgG and complement (C3d). There were no warm autoantibodies or alloantibodies present in his serum or in an eluate from his RBCs. A cold agglutinin screen showed the presence of an IgM cold agglutinin, strongly reactive above 30 1C. The Donath-Landsteiner test was negative, which excluded paroxysmal cold hemoglobinuria.
His CYA was discontinued, as this drug has been associated with the hemolytic uremic syndrome. A trial of methylprednisolone was initiated, but his Hb continued to fall (7.8-4.7 g/100 ml) despite transfusions. A dose of rituximab (375 mg/m 2 ) was given i.v. A total of four units of packed RBCs were transfused during the first 3 days following the first dose of rituximab. Methylprednisolone was rapidly tapered, and a second dose of rituximab was given a week after the first dose. He was then able to maintain his Hb at 6.5-7 g/100 ml without transfusions, and was discharged 2 days later with an Hb of 7.6 g/100 ml (see Figure 1) .
Nine days later, the patient was admitted to an outside hospital for fever and hypotension. He was started empirically on broad-spectrum antibiotics. Blood cultures from his indwelling catheter grew enterococcal species and Serratia rubidaea. Laboratory evaluation showed mild anemia, elevated bilirubin and lactate dehydrogenase, consistent with resolving hemolytic anemia. The cold agglutinin was still present, but was only moderately reactive at room temperature and not reactive at 30 1C. He was transfused with two units of packed RBCs before transfer to our facility. The patient received a third dose of rituximab and his central line was removed. His Hb rose from 7.0 to 10.0 g/100 ml without further transfusions. Before discharge, he was given a fourth dose of rituximab. At outpatient visits over the next 4 months, he continued to do well with no recurrence of hemolysis or infectious complications. His Hb gradually increased to 13.6 g/100 ml, and has since remained stable.
Rituximab is a monoclonal chimeric mouse/human IgG Ab that binds to CD20 Ags, which are found on most normal and malignant B cells. Owing to its anti-B-cell activity, rituximab has been used in the treatment of B-cell malignancies. Although the mechanisms are not well understood, rituximab has also been shown to be effective in the treatment of refractory AIHA in adult and pediatric patients in the non-HSCT setting, including in the treatment of cold AIHA. 7 In the HSCT setting, encouraging results in both adult 8 and pediatric patients 9,10 with warm AIHA have been reported. To our knowledge, there is only one existing report of the use of rituximab in post-HSCT cold AIHA. 5 Their patient was a 37-month-old boy with b-thalassemia major, who presented with severe cold AIHA on day þ 180 after an unrelated T-cell-non-depleted HSCT. His Hb dropped from 10 to 6.7 g/100 ml in 1 week. The patient failed to respond to high-dose methylprednisolone or i.v.Ig. Two doses of rituximab (375 mg/m 2 ) were administered i.v. a week apart and the hemolysis was resolved.
Our experience and that of Hongeng et al. 5 show that severe cold AIHA arising after HSCT can be successfully treated with rituximab with prompt and dramatic responses. Considering the failure of post-HSCT AIHA (both warm and cold varieties) to respond to conventional therapies, and the high mortalities in this setting, alternatives such as rituximab should be considered early. 
